Abstract: In order to achieve a charging service using an outlet of 100 V or 200V, the present invention provides a management server 10 including an acquisition unit 11 that acquires, from a user terminal, apparatus specifying information specifying a control apparatus that controls power supply to an outlet, and a control execution unit 12 that executes processing of controlling the control apparatus specified by the apparatus specifying information.

Abstract: The present invention addresses the problem of a providing NMN having high purity and a low impurity content. The present invention is a high-purity ?-nicotinamide mononucleotide (NMN) which has a purity of 99.0 mass % or higher and in which the amounts of C11H15NO9P, C10H16N5O10P2, C9H15N3O8P, C9H15N3O7P, C9H16N4O8P, C10H15N5O7P, and C21H27N6O15P2 contained as impurities are equal to or less than a detection limit.

Abstract: [PROBLEM] To provide a sperm motility improvement agent that is highly safe and may effectively improve sperm motility. [SOLUTION] A sperm motility improvement agent comprising nicotinamide mononucleotide as an active ingredient.

Abstract: [PROBLEM] To provide a coenzyme Q production accelerator that allows increasing an intracellular coenzyme Q level. [SOLUTION] The present invention is a coenzyme Q production accelerator containing nicotinamide mononucleotide as an active ingredient.

Abstract: PROBLEM: To provide a food, a drink, or the like for infant that allows improving an intestinal environment and enhancing an immune strength of an infant. SOLUTION: A food or drink for infant containing an effective dose of nicotinamide mononucleotide.

Abstract: PROBLEM: To provide an anti-aging agent and a method for the anti-aging that are safe in long-term intake and ensures effective suppression of the progress of the aging. SOLUTION: Nicotinamide mononucleotide is contained as an active ingredient.

Abstract: PROBLEM: To provide an anti-aging agent and a method for the anti-aging that are safe in long-term intake and ensures effective suppression of the progress of the aging. SOLUTION: Nicotinamide mononucleotide is contained as an active ingredient.

Abstract: PROBLEM: To provide a cosmetic composition that has a moisturizing effect that gives lasting moisture to a skin, an effect that prevents or improves aging symptoms, such as wrinkles and sags, and similar effect. SOLUTION: Nicotinamide mononucleotide is contained in a cosmetic composition.

Abstract: Provided herein are compositions and methods for improving a visual function, e.g., eyesight, eye strain, blurred vision, dry eye, retinal function, presbyopia, or Visual Display Terminal (VDT) syndrome, that is safe for long-term intake and ensures effective improvement of visual function. The compositions include a nicotinamide mononucleotide (structure shown below) as an active ingredient.

Abstract: PROBLEM: To provide an anti-aging agent and a method for the anti-aging that are safe in long-term intake and ensures effective suppression of the progress of the aging. SOLUTION: Nicotinamide mononucleotide is contained as an active ingredient.

Abstract: PROBLEM: To provide an improving agent and an improving method for a visual function that is safe in long-term intake and ensures effective improvement of the visual function. SOLUTION: Nicotinamide mononucleotide is contained as an active ingredient.

Abstract: PROBLEM: To provide an improving agent and an improving method for a sleep disorder that is safe in long-term intake and ensures effective improvement of the sleep disorder. SOLUTION: Nicotinamide mononucleotide is contained as an active ingredient.

Abstract: A via model generation method includes: acquiring via arrangement information including a hole diameter of a via formed in a board including a plurality of wiring layers, a clearance distance between a ground conductor formed in one wiring layer of the plurality of wiring layers and the via, and a ground via distance between the via and a ground via coupled to the ground conductor; acquiring board information including a relative dielectric constant of the board; calculating a capacitance component of the via by a first electromagnetic field analysis using the hole diameter of the via, the clearance distance, and the relative dielectric constant of the board; calculating an inductance component of the via by a second electromagnetic field analysis using the hole diameter of the via, the ground via distance, and the relative dielectric constant of the board; and generating a via model including the capacitance and inductance components.

Abstract: A wiring board includes a core, and a differential signal wire disposed on a surface of the core, wherein the core includes a glass cloth formed such that a warp yarn and a weft yarn that are each formed of a glass fiber are woven, a resin in which the glass cloth is embedded, and a powder that disperses in a stitch of the glass cloth that is surrounded by the warp yarn and the weft yarn and that is formed of a material having a relative permittivity more than a relative permittivity of the resin.

Abstract: A via model generation method includes: acquiring via arrangement information including a hole diameter of a via formed in a board including wiring layers, clearance distance between a ground conductor formed in one of the wiring layers and the via, and ground via distance between the via and a ground via coupled to the ground conductor; acquiring, by a computer, board information including a relative dielectric constant of the board; calculating a capacitance component of the via by a first electromagnetic field analysis with use of the hole diameter of the via, the clearance distance, and the relative dielectric constant of the board; calculating an inductance component of the via by a second electromagnetic field analysis with use of the hole diameter of the via, the ground via distance, and the relative dielectric constant of the board; and generating a via model including the capacitance component and the inductance component.

Abstract: A circuit board includes: a first surface and a second surface opposite to the first surface; a through hole extending between the first surface and the second surface; a conductor covering an inner wall surface of the through hole, a first end and a second end of the conductor being terminated inside the through hole; and a wire connected to the conductor, wherein a sum of a length from a contact portion where the conductor contacts a connector pin inserted in the through hole to the first end of the conductor, and a length from a wire connecting portion where the conductor is connected to the wire to the second end of the conductor is 0.5 mm or less.

Abstract: A circuit board includes: a first surface and a second surface opposite to the first surface; a through hole extending between the first surface and the second surface; a conductor covering an inner wall surface of the through hole, a first end and a second end of the conductor being terminated inside the through hole; and a wire connected to the conductor, wherein a sum of a length from a contact portion where the conductor contacts a connector pin inserted in the through hole to the first end of the conductor, and a length from a wire connecting portion where the conductor is connected to the wire to the second end of the conductor is 0.5 mm or less.

Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.

Abstract: An antibody capable of binding to a specific region of glypican 3, as well as a humanized antibody created based on that antibody are disclosed. The anti-GPC3 antibody of the invention has a higher ADCC activity and CDC activity compared with those of a conventional antibody. The antibody of the present invention is useful as a cell growth inhibitor, an anticancer agent and an agent for diagnosis of cancers.

Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.